‘Beating heart’ transplants could boost success rate

‘Beating heart’ transplants could boost success rate

January 11, 2012

Amy DeStefano was a single mother juggling family life and a full-time job three winters ago when she caught what at first was just a persistent February cold. Then it spiraled into pneumonia and spread to her heart.
 
By last January, DeStefano, at 39, was on the waiting list for a heart transplant at Massachusetts General Hospital.
 
Her wait ended late last month when the social worker from Portsmouth, N.H., became the first patient in New England to receive an experimental “beating heart’’ transplant.

Receptos, Inc.

Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology

Receptos Achieves Milestone Under License of G-Protein Coupled Receptor Crystal Structure Determination Technology

January 10, 2012

SAN DIEGO, Jan. 10, 2012 -- Receptos Inc. today announced the successful achievement of the technology transfer milestone under its license and technology transfer deal with Janssen Pharmaceuticals, Inc. (formerly Ortho-McNeil Janssen Pharmaceuticals, Inc.), for Receptos' breakthrough GPCR crystal structure determination technology.

FLAGSHIP VENTURES CLOSES $270 MILLION EARLY-STAGE VENTURE CAPITAL FUND

FLAGSHIP VENTURES CLOSES $270 MILLION EARLY-STAGE VENTURE CAPITAL FUND

January 11, 2012

Cambridge, Mass. – Jan. 11, 2012 – Flagship Ventures, a leading venture capital firm focused on healthcare and sustainability, today announced the year-end 2011 close of its largest fund to date, raising $270 million for Flagship Ventures Fund IV L.P., exceeding its target of $250 million. Investors in Flagship Ventures Fund IV include pension funds, foundations, fund-of-funds, corporations and individuals. Joining prior fund investors were several new limited partners.

BG Medicine, Inc.

BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer

BG Medicine, Inc. Appoints Eric Bouvier as Chief Executive Officer

January 9, 2012

WALTHAM, Mass., Jan. 9, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), a company focused on the development and commercialization of novel, biomarker-based diagnostics, announced today that its Board of Directors has appointed Eric Bouvier, Ph.D., as the company's new President and Chief Executive Officer and a member of the Board of Directors, effective as of January 9, 2012.

Blend Therapeutics Founded by Leading Researchers in Chemistry and Nanomedicine to Develop a New Class of Integrative Combination Medicines

Blend Therapeutics Founded by Leading Researchers in Chemistry and Nanomedicine to Develop a New Class of Integrative Combination Medicines

January 6, 2012

WATERTOWN, Mass., Jan 06, 2012 (BUSINESS WIRE) -- Blend Therapeutics, a biotechnology company discovering and developing a new class of integrative combination medicines, announced the company's founding and strategic mission to develop innovative combination medicines with novel pharmacological profiles designed to target distinct disease pathways with optimal efficacy and safety.

Avedro, Inc.

Avedro Announces CE Approval for Lasik Xtra ™

Avedro Announces CE Approval for Lasik Xtra ™

January 4, 2012

Waltham, Massachusetts, USA, January 4, 2012 -- Avedro, Inc. announced today that the Company’s proprietary Lasik Xtra procedure has received CE Approval. Lasik Xtra is a two minute procedure used in conjunction with standard Lasik to restore the biomechanical integrity and strength to the cornea after a Lasik procedure. Lasik Xtra has been successfully used in thousands of Lasik surgeries outside the US.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

Ensemble Therapeutics Advances Macrocycle IL-17 Antagonist Program: Reports First Known Small Molecule Inhibitors of Important Autoimmune Target

January 5, 2012

CAMBRIDGE, MA – January 5, 2012 -- Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today that the company has identified a series of unique small molecule antagonists of Interleukin-17, a pro-inflammatory cytokine implicated in multiple inflammatory and autoimmune diseases such as psoriasis, rheumatoid arthritis, Crohn’s and intestinal bowel disease.

Ensemble Therapeutics Corporation

Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

Ensemble Therapeutics Extends Macrocycle Drug Discovery Alliance with Bristol-Myers Squibb

January 5, 2012

CAMBRIDGE, MA – January 5, 2012 -- Ensemble Therapeutics, a biotechnology company developing EnsemblinsTM, a novel class of small molecule therapeutics with the power of biologics, announced today the extension of its strategic alliance with Bristol-Myers Squibb (NYSE: BMS), building on a collaboration initiated in April 2009.

CIA's In-Q-Tel makes strategic investment in Quanterix

CIA's In-Q-Tel makes strategic investment in Quanterix

January 5, 2012

Quanterix Corp. has taken a strategic investment for an undisclosed amount from In-Q-Tel, the investment arm of the CIA, to help expand development of its technology to detect pathogens.

Please click on Mass High Tech logo to view full article

Drawing blood with a tap, not a sting - Cambridge firm’s device uses tiny needles, vacuum for painless diagnostic tests

Drawing blood with a tap, not a sting - Cambridge firm’s device uses tiny needles, vacuum for painless diagnostic tests

January 2, 2012

Pop culture has developed an appetite for blood, but the average American still cowers at the sight of a needle.

What if giving blood was as easy and painless as a tap on the arm? Engineers at Seventh Sense Biosystems in Cambridge have been working for two years to make that so. And they are getting close.
 

Please click on Boston.com logo to view full article.